Osama Batayneh

Dr. Osama Batayneh

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2022 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
OBOsama Batayneh
Osama Batayneh
ALAmy Lin
Amy Lin
OAOmar Abu-Jaradeh
Omar Abu-Jaradeh
PWPeter Wu
Peter Wu
MVMauricio F. Villamar
Mauricio F. Villamar
PSPurva Sharma
Purva Sharma
Central nervous system (CNS) involvement in patients with chronic lymphocytic leukaemia (CLL) is very rare and, when present, it is frequently asymptomatic. Rather, CNS involvement is more common in other haematological malignancies such as mantle cell lymphoma or diffuse large B cell lymphoma. The paucity of literature on CNS involvement in CLL underscores the importance of increasing awareness about its presentation, diagnosis and optimal management. We describe a case of symptomatic leptomeningeal leukaemic involvement as an atypical presentation of CLL relapse. A favourable clinical response was observed following systemic monotherapy with venetoclax.

2 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
OBOsama Batayneh
Osama Batayneh
MMMahmoudreza Moein
Mahmoudreza Moein
NNNour Sabiha Naji
Nour Sabiha Naji
APAnsy Patel
Ansy Patel
AMAnupa R. Mandava
Anupa R. Mandava
KGKrishna B. Ghimire
Krishna B. Ghimire
Background: The KMT2A (MLL1) gene is altered in a variety of hematological malignancies and solid tumors. KMT2A-rearranged (KMT2Ar) AML represents a distinct subtype associated with poor outcomes and high relapse rate despite initial responsiveness to chemotherapy. Methods: A total of 3863 cases of AML peripheral blood samples were analyzed using the FoundationOne Heme combined comprehensive hybrid capture-based DNA and RNA sequencing assay. Results: Of the 3863 AML cases, 521 (13.4%) featured genomic alterations (GAs) in the KMT2A gene, 99.1% of which were large rearrangements (KMT2Ar). A total of 56.9% were males with a median age of 62 years. Of the KMT2Ar cases, there were 43.1% KMT2A duplications, 52.7% fusions, and 4.2% not otherwise specified rearrangements. A total of 0.9% of the KMT2A-altered AML cases were short variant mutations. There were no KMT2A (0%) amplifications or deletions. KMT2Ar cases were associated with increased GA frequencies in FLT3 (27.3% vs. 19.8%; p = 0.0002), KRAS (17.2% vs. 7.8%; p < 0.0001) (overall; 1.1% KRAS G12C), and IDH2 (16.0% vs. 10.4%; p < 0.0001), while KMT2A wild-type AML (KMT2Awt) had significantly increased GA frequencies in RUNX1 (20.7% vs. 15.8%; p = 0.0081), ASXL1 (16.6% vs. 10.5%; p = 0.0003), and TET2 (16.4% vs. 10.1%; p = 0.0002), NPM1 (17.5% vs. 0.2%; p < 0.0001), and TP53 (17.8% vs. 7.9%; p < 0.0001). Conclusions: KMT2A rearrangements are common in AML (13.4% of cases featured KMT2Ar). A total of 99.1% of alterations in KMT2A are large rearrangements, with fusions being the most commonly observed alteration (52.7% of total rearrangements). No amplifications or deletions were seen. This genomic landscape study highlights significant genomic differences between KMT2Ar and KMT2Awt AML patients, which may enrich our understanding of the molecular profile and clusters of mutations in AML.

20 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
OBOsama Batayneh
Osama Batayneh
MMMahmoudreza Moein
Mahmoudreza Moein
AGAlexandra Goodman
Alexandra Goodman
DDDevashish Desai
Devashish Desai
DPDean Pavlick
Dean Pavlick
KGKrishna Bilas Ghimire
Krishna Bilas Ghimire
Background/Objectives: This study investigates genomic alterations (GA) between NPM1-mutated (NPM1mut) and wild-type (NPM1wt) acute myeloid leukemia (AML), aiming to better understand the AML genomic profile. NPM1mut AML represents a distinct clinical AML subtype with high relapse rates despite initial responsiveness to chemotherapy. Methods: A total of 4206 AML cases from 2019 to 2024 were analyzed using the FoundationOne Heme assay, incorporating comprehensive DNA and RNA sequencing. Patients were stratified into NPM1mut and NPM1wt cohorts, and genomic differences were systematically compared between the two groups. Results: Among 4206 cases, 633 (15.1%) featured NPM1 GA, with over 99% exhibiting short variant mutations. NPM1mut AML was more common in females (53.4% vs. 41.5%) and associated with a slightly higher median age (62 vs. 60 years). GA was more frequent in NPM1mut AML compared to the NPM1wt and included DNMT3A (39.2% vs. 12.6%; p < 0.0001), PTPN11 (18.3% vs. 7.5%; p < 0.0001), FLT3 (54.5% vs. 14.7%; p < 0.0001), IDH1 (16.1% vs. 5.6%; p < 0.0001), IDH2 (19.0% vs. 9.0%; p < 0.0001), TET2 (23.4% vs. 13.5%; p < 0.0001), and WT1 (12.5% vs. 9.4%; p = 0.02). GA was more frequent in NPM1wt AML and included ASXL1 (17.1% vs. 3.6%; p 0.0001), BCOR (7.5% vs. 1.6%; p < 0.0001), KMT2A (14.7% vs. 0.2%; p < 0.0001), RUNX1 (22.5% vs. 1.9%; p 0.0001), STAG2 (6.9% vs. 1.6%; p < 0.0001) and TP53 (19.1% vs. 4.1%; p < 0.0001). Conclusions: Mutations linked to therapy targets in AML, such as (FLT3 and IDH1/2), PTPN11, and DNMT3A (both associated with inferior outcomes), are more commonly observed in NPM1mut AML, whereas KMT2A, TP53, and myelodysplastic-related mutations are more commonly observed in NPM1wt AML.

1 June 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RMRatib Mahfouz
Ratib Mahfouz
MMMahmoud Mansour
Mahmoud Mansour
AOAdham E. Obeidat
Adham E. Obeidat
MDMohammad Darweesh
Mohammad Darweesh
OBOsama Batayneh
Osama Batayneh
GGGhulam Ghous
Ghulam Ghous
E19054 Background: Hematopoietic stem cell transplantation (HSCT) recipients are at an increased risk for Clostridioides difficile infections (CDI). Despite it being the main cause of nosocomial enterocolitis in this group of patients, diagnosis of CDI remains challenging and carries significant morbidity and mortality. This is usually due to multiple comorbidities, recurrent antibiotics administration, prolonged immunosuppression, and lengthy hospitalization. This study aims to look more into outcomes and predictors of CDI in HSCT patients in terms of incidence, and mortality. Methods: The United States Nationwide Inpatient Sample was used to extract hospitalization data of patients admitted between 2016 to 2019. Using ICD10 revision codes, we identified adults with a discharge diagnosis of CDI and concomitant HSCT. The control group included non-HSCT patients with CDI. The primary outcome was in-hospital mortality. Secondary outcomes were the length of stay (LOS) and hospital charges. Additionally, predictors for developing CDI and dying from CDI were calculated in HSCT patients. Multivariate logistic regression was used to adjust for relevant variables. Results: An estimated 1,235,465 patients were admitted with CDI during the study period. CDI incidence per 100 discharges was higher among HSCT patients at 4.0% vs. 1.0% in the general population. After adjusting for comorbidities and demographic variables, HSCT was independently associated with increased odds of mortality (adjusted odds ratio [AOR] 1.47 (95%CI 1.20-1.80 and P <0.01). Mean length of stay and hospital charges increased by 1.76 days (95%CI 0.90-2.62, P < 0.01) and $59,023 (95%CI $35,940-$82,105, P < 0.01), respectively, in the HSCT group. In the HSCT group, patients with severe liver disease, malnutrition, and graft vs. host disease showed a significantly higher incidence of CDI. Predictors of mortality of HSCT patients and CDI are outlined in the attached table. Conclusions: HSCT recipients are at an increased risk for CDI compared to general population. LOS, total hospital charge, and mortality rate were significantly higher. The risk of CDI was found to be significantly higher in patients with moderate to severe liver disease, graft vs host disease, and malnutrition. The odds of mortality were found to be the highest in patients older than 65 years and those with congestive heart failure, moderate to severe liver disease, graft vs host disease, or malnutrition.

1 August 2025 in Journal of Hematology
Verified
Journal Article
Open access
PDF file
OBOsama Batayneh
Osama Batayneh
DPDeevyashali Parekh
Deevyashali Parekh
MAMargarita Vazquez Almonte
Margarita Vazquez Almonte
CHCristina Hamacher
Cristina Hamacher
AGAngela Gupta
Angela Gupta
TGTeresa Gentile
Teresa Gentile
Background: While molecular and cytogenetic testing may change prognosis and guide treatment intensity for patients with acute myeloid leukemia (AML), timing from diagnosis to treatment (TDT) on the other hand may impact treatment outcomes and survival. These considerations are sometimes at odds with each other given that molecular studies can take up to 2 weeks to result. Methods: A retrospective cohort analysis was conducted at SUNY Upstate University Hospital to examine the effect of TDT on complete remission (CR) and overall survival (OS). The subjects were at least 18 years old and diagnosed with AML and treated between January 2010 and June 2024. TDT was divided into three categories: chemotherapy induction within 1 - 5, 6 - 10, and 11+ days. Univariate Kaplan-Myer survival analysis and multivariate Cox regression model were performed. Results: A total of 187 patients were included, and 34% (n = 64) were younger than age 60. Patients were classified as 20% (n = 37) favorable, 36% (n = 67) intermediate, and 40% (n = 74) adverse risk, , while 4% risk stratification could not be completed due to missing data. Seventy-two percent (n = 134) had de novo AML. Chemotherapy induction began for 70% (n = 130) on days 1 - 5, 16% (n = 30) between days 6 - 10, and 14% (n = 27) on day 11 or after. The probability of achieving CR decreases for those who had induction 11+ days from diagnosis compared to those who had induction 1 to 5 days from diagnosis. This relationship was statistically significant (odds ratio = 0.32, 95% confidence interval (CI): 0.125 - 0.796; P = 0.003). However, no differences in OS and CR between TDT groups were seen when multivariate analysis was performed. Conclusion: Our retrospective study showed no difference in OS based on TDT groups, which supports clinicians’ approach to await on comprehensive AML profiling for an optimal risk stratification at diagnosis and implementing best course of action.

2 November 2023 in Blood
Verified
Journal Article
Open access
OBOsama Batayneh
Osama Batayneh
AIAmbreen Ijaz
Ambreen Ijaz
ATAhmad Toumar
Ahmad Toumar
JMJessica Meek
Jessica Meek
HAHouda Abdelrahman
Houda Abdelrahman
TMTaro Minami
Taro Minami
Background: Diagnosis and treatment of subsegmental pulmonary embolism (SSPE) are challenging. Contrary to segmental PE, little is known about the accuracy of the diagnosis of SSPE Methods A retrospective matched cohort study was conducted at a university-affiliated community hospital. Computed tomographic angiography (CTAs) were reviewed from August 2018 to December 2021. Patients who were 18-year-old or older with the diagnosis of SSPE were included. Patients with a concurrent segmental PE or deep venous thrombosis (DVT) were excluded. Another radiologist reviewed each CTA. Results Total of 43 patients with SSPE without segmental PE were identified. The mean age of subjects was 67 years. 24 (56%) patients were males, and 41 (95%) were white. 42 (97%) of CTAs were performed for suspected PE. One case was found incidentally. Forty patients (93%) received therapeutic anticoagulation. Three patients (7%) were discharged from the Emergency Department (ED) without therapeutic anticoagulation. The average duration of anticoagulation therapy was four-months. Another radiologist's review of the CTA on admission revealed a discordant diagnosis: 13 out of 43 (30%) cases were reported negative for SSPE. One case was reported for segmental PE Conclusion The accuracy of the diagnosis of SSPE is low as the discordance rate by different radiologists is high.More studies are needed to establish the diagnosis and guide treatment of SSPE.